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The mechanism by which eosinophil leukocytes migrate into the site of immediate- 
type hypersensitivity reactions has  been difficult to  study in vivo because of  the 
large numbers of variables in any experimental design. Certain of  these difficulties 
have been overcome by the use of a modification of the in vitro Millipore technique 
of  Boyden by which the eosinophilotactic properties of  substances can be directly 
measured. Using this technique, it was shown that guinea pig IgG1 or IgG2, as pre- 
formed antigen-antibody complexes,  could both generate from whole serum a factor 
which  was  specifically  chemotactic  for  eosinophils  (ECF-C)  1 and  was  apparently 
identical to C5a  (1). 
An earlier report  (2),  using cell counts in guinea pig skin, had shown that both 
IgG1 and IgG~, as prefonlaed complexes,  also prepared the tissue for  a  subsequent 
local eosinophilia 12 hr after injection. However, if antibody was first placed in the 
skin and after a variable latent period the animal was challenged with antigen and 
Evans blue dye intravenously (as in a usual passive cutaneous anaphylactic reaction), 
IgGL but not IgG2 elicited a local eosinophil response 8-12 hr after the initial blueing 
reaction (2). 
It was the purpose of the present study to determine whether tissue, actively 
sensitized or passively sensitized with IgG1, but in the absence of serum, can 
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1  In this presentation, an eosinophil chemotactic factor (ECF) derived from whole guinea 
pig serum by  treatment  either  with  antigen-antibody complexes (1)  or  with  zymosan,  2 
which appears to be identical with C5a and therefore a product of the interaction of comple- 
ment proteins, is termed ECF-C. Material selectively attracting neutrophils, also of comple- 
ment origin (1) but having a larger molecular size, is termed NCF-C. A factor with eosino- 
philotaetic activity appearing in association with immediate-type hypersensitivity reactions 
and generated in the apparent  absence of a complement requirement is designated ECF-A. 
Other abbreviations used in this paper: DNP-BGG, dinitrophenol conjugates of bovine gamma 
globulin; DNP-BSA, dinitrophenol conjugates of bovine serum albumin; SRS-A, slow react- 
ing substance  of anaphylaxis;  zym  G/P, zymosan-treated  guinea pig. 
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release  an  eosinophilotactic  agent  after  the  addition  of  specific  antigen  and 
whether  such  an agent is the  same or  different from  that  produced  from  the 
interaction  of  serum  with  preformed  antigen-antibody  complexes  (1)  or 
zymosan3 For this purpose,  an in vitro model involving the  release  of chemi- 
cal  mediators  from  guinea pig  lung was  used,  which  has  been  employed  by 
numerous workers as a  model of immediate-type hypersensitivity in the guinea 
pig  (4-7).  It has  enabled the definition of  an  immunoglobulin mediating  the 
release of pharmacological agents (6,  7)  and allowed the mediators  themselves 
to be quantitated (4,  7). This report,  therefore,  combines two in vitro systems, 
namely  the  Millipore  technique  for  measuring  chemotaxis  and  an  in  vitro 
model of anaphylaxis. 
Materials and Methods 
Materials were obtained as follows: histamine acid phosphate, zymosan, serotonin creat- 
inine sulphate, and succinic acid (Mann Research Labs. Inc., New York); bradykinin triaee- 
tate (Sandoz Pharmaceuticals, Basel, Switzerland); prostaglandins PGE1, PGE2,  and PGF2~ 
(generously supplied by Dr. John Pike of the Upjohn Co.,  Kalamazoo, Mich.); maleic acid 
(Hopkin  &  Williams, Ltd.,  Chadwell Heath,  Essex,  England); blue dextran  (Pharmacia 
Fine Chemicals Inc., New Market, N. J.); glucagon (Nutritional Biochemicals  Corporation, 
Cleveland, Ohio); vitamin B12 (Wyeth Laboratories, Philadelphia, Pa.); glycogen (J. T. Baker 
Chemical Co., Phillipsburg, N. J.); horse serum (Grand Island Biological Co.,  Grand Island, 
N. Y.); ovalbumin, five times crystallized (Pentex Biochemical,  Kankakee, Ill.); and guinea 
pig serum  (Pel-Freez Biologicals,  Inc., Rogers,  Ark.). 
Dinitrophenol conjugates  of  bovine gamma  globulin  (DNP-BGG)  and  bovine serum 
albumin (DNP-BSA) were prepared according to the method of Benacerraf and Levine (8) 
and contained 40 and 20 haptenic groups per molecule, respectively. Partially purified cobra 
venom was prepared as previously described (9). The titer of "late acting" complement com- 
ponents was estimated in microtiter plates using equal volumes of 1 )<  10  s sensitized  sheep 
erythrocytes prepared with the first component of guinea pig complement and the fourth 
component of human complement (EAClgp4~'u), 50 effective molecules of guinea pig second 
component (C2), and doubling dilutions of guinea pig serum as a source of terminal compo- 
nents. The plates were incubated for 30 min each  at 30  ° and 37°C  and centrifuged at 100 
rpm for 5 min at 4°C.  The 50% lytic endpoint was determined by inspection. The guinea 
pig serum was obtained by cardiac puncture before and after the intravenous injection of 1 
ml of cobra venom factor or Tyrode's solution. 
Guinea pig IgGx and IgG2 7S immunoglobulin  fractions were prepared as follows. Antisera 
to ovalbumin were prepared in guinea pigs following the same injection schedule as previously 
described  for raising guinea pig antiserum to ferritin (2). The antiserum was fractionated by 
diethylaminoethyl (DEAE)-cellulose chromatography (1). The functional purity of the IgG1- 
and IgG:-containing fractions was tested by passive cutaneous anaphylaxis and by passive 
hemolysis as described  by Bloch et al.  (10) and by immunoelectrophoresis and gel diffusion 
using rabbit anti-7S IgG and specific anti-guinea pig IgG1 (2). Passive hemagglutination was 
performed as previously described  (10). 
Preparation of Lung Tissue for the In Vitro Release of Mediators.--Whole lung: The heart 
and lungs from guinea pigs were  excised  and perfused free  of visible blood with Tyrode's 
solution as previously described (4). Animals were actively sensitized with DNP-BSA by the 
2 A. B. Kay. Unpublished observations. 604  EOSINOPHIL  CHEMZOTACTIC FACTOR IN  ANAPI-IYLAXIS 
method of Benacerraf et al.  (11), or with ovalbumin in phenol (5), or by a single injection of 
200 Dg of ovalbumin in complete Freund's adjuvant into each hind footpad. The lungs of ac- 
tively sensitized animals were challenged with 4  mg of antigen (ovalbumin or DNP-BGG) 
via the pulmonary artery and the perfusate was collected for 30 mix after antigen challenge. 
The perfusates were placed on ice  and  assayed the same day for histamine and slow  react- 
ing substance of anaphylaxis (SRS-A)  according to the method of Brocklehurst (4), and for 
chemotaxis as described below.  Some perfusates were tested after a single freezing at --70°C 
and rapid thawing. 
Lung fragments:  In experiments using lung fragments the perfused tissue was sliced with 
fine scissors, washed in Tyrode's solution, and divided into 300 mg portions using an overhead 
weighing balance. With actively sensitized lung,  the portions were suspended in 2.5  ml of 
Tyrode's solution to which was added the antigen suspended in 0.5 ml of Tyrode's solution. 
The samples were gently agitated in a water bath at 37°C. For passive sensitization, the lung 
fragments were suspended in 1.8 ml volumes of fractions containing antibody at 37°C. After 
the incubation period the fragments were washed twice and resuspended in 2.5 ml of Tyrode's 
solution. Antigen was then added as for the actively sensitized lung. After incubation with 
antigen the diffusates were removed with a Pasteur pipette and assayed for histamine, SRS-A, 
and chemotaxis. In all studies using lung fragments the values for chemotaxis, histamine re- 
lease, and SRS-A release represent the mean of duplicate samples. For all three measurements 
the values obtained with duplicate samples varied by less than 15%. 
Some experiments with lung  fragments were modified as  follows.  In  experiments with 
ethylenediaminetetraacetate (EDTA), the samples were washed once either with Ca  ++- and 
Mg++-free Tyrode's, containing 5 m~t EDTA,  or in  the case of the control samples, with 
Ca  ++- and Mg++-free Tyrode's containing EDTA in which Ca  ++ and Mg  ++ had been  re- 
placed before the addition of antigen. The reconstituted Tyrode's solutions were adjusted by 
adding 6.8 m~ of Ca++ and 1 m~ of Mg  ++. The effect of succinate or maleate was studied 
using 5 m~ concentrations in Tyrode's solution adjusted to pH 7.4 with 0.1 1~ NaOH. Antigen 
was added to actively or passively sensitized fragments 1 mix after incubation of the lung 
samples with maleate or succinate. The diffusate from the samples challenged with antigen 
alone was tested for chemotaxis in the presence of 5 mM of succinate or maleate. 
Measurement  and  Fractionation  of Eosinophil  Chemotactic Activity of tltv Anaphylactic  Re- 
action Mixture.-- 
Measurement  of ehemotaxls: A modification of the Millipore technique of Boyden was used 
as previously described (1). Guinea pig eosinophils were obtained by peritoneal lavage from 
animals which had received multiple injections of horse serum (1). Neutrophils were harvested 
from the peritoneal cavity of animals injected with glycogen 3-6 hr previously. For measuring 
eosinophil migration an 8.0 It pore size was used and for neutrophils 1.2 bt, 3.0 #,  and 8.0 # 
pore sizes were employed. 
In the assay for chemotaxis, Tyrode's solution containing 0.5%  ovalbumin was used in 
both the cell and the test compartments. Zymosan-treated  guinea pig (zym G/P) serum served 
as a  reference pool of material having both eosinophil and neutrophil chemotactic activity. 
Zymosan which had been boiled and washed twice in distilled water was incubated for 30 
mix at 37°C with guinea pig serum using 20 mg of zymosan/ml of serum. The zymosan was 
removed by centrifugation and the serum subsequently heated at 56°C for 30 mix. Samples 
were stored at -70°C until used. 
In experiments using the perfusate from whole lung, a value for the total chemotactic ac- 
tivity of the perfusate was expressed as V )<  C. V represented the volume of the perfusate 
and C the percentage chemotaxis of 1 ml of peffusate as compared with 0.1 ml of a zymosan- 
treated reference serum when both were tested against the same suspension of eosinophils. 
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0.6 ml volumes to which were added 0.1 ml of 5% ovalbumin and 0.3 ml of Tyrode's solution. 
When the release of SRS-A and histamine was low, 0.9 ml volumes of the diffusate was used. 
The chemotactic counts were expressed as the mean cell count of five high power fields (1). 
Fractionation  of chemotactic activity  by gel filtration  chromatography:  A Sephadex G-25 col- 
umn (40 X  1 cm) was equilibrated using Tyrode's solution as a  buffer. In each experiment, 
1 ml of lung supernate was applied and 1 ml fractions were collected. The column was stand- 
ardized by preliminary fractionation of various substances of known molecular weight. The 
tubes containing the highest concentration of blue dextran and vitamin B12 were read visually. 
The peak of glucagon was recorded at 280  In# using a  DU-2 Beckman spectrophotometer 
(Beckman Instruments, Inc., Palo Alto, Calif.). 
~j 
\ 
Lu 
60 
50 
40-- 
30- 
20-  • 
lO-- 
.'.t  0. 
IxlO  3 
B  • 
I  I 
2xlO 3  3x  10 3 
TOTAL EOSINOPHIL CHEMOTACTIC ACTIVITY 
FIG. 1. Relation between the total amount of lung histamine released and the total chemo- 
tactic activity, V X  C  (see Methods), of the perfusate from sensitized lung following  chal- 
lenge with antigen. The animals were killed at  various time intervals following  an initial 
sensitizing injection. The  data  on  individual animals sensitized with ovalbumin either in 
complete Freund's adjuvant or phenol are depicted. Correlation coefficient  =  0.48;  number 
of samples =  27;  0.02  >  P  >  0.01. 
RESULTS 
The Antigen-Induced  Release In  Vitro  of an Eosinophil  Chemotactic  Factor 
from Actively Sensitized Guinea Pig Lung.--When guinea pig lungs from actively 
sensitized animals were perfused free of visible blood via the pulmonary artery 
and subsequently challenged with specific antigen,  the perfusate contained,  in 
addition  to histamine  and SRS-A, a factor specifically chemotactic for guinea 
pig eosinophil leukocytes. This eosinophil chemotactic factor of anaphylaxis has 
been designated  ECF-A.  ECF-A was measured in the perfusate from animals 
sensitized  with  either  ovalbumin  or  DNP-BGG  and  challenged  with  oval- 
bumin  or  DNP-BSA,  respectively. A  single  injection  of  ovalbumin  given  in 606  EOSINOPHIL CHEMOTACTIC FACTOR IN ANAPHYLAXIS 
complete Freund's adjuvant  was slightly better than ovalbumin in phenol for 
preparing  guinea  pigs  for  the  specific  antigen-induced  release  of  histamine, 
SRS-A,  and  ECF-A.  Sensitization  for  the  release  of  all  these  mediators was 
observed l0 days after the administration of ovalbumin in phenol or complete 
Freund's adjuvant but was not pronounced until 3 wk or later and was satisfac- 
tory up  to 8  wk,  at which  time the  study was  terminated.  The  relationship 
between the total quantity of specific antigen-induced release of histamine and 
ECF-A from the lungs of each animal is shown in Fig.  1. A similar direct rela- 
tionship was also demonstrated between  the  total amount of SRS-A released 
and the total ECF-A activity. 
Studies were next carried out to determine whether ECF-A  could be released 
from fragments of actively sensitized lung, and the results are shown in Table I. 
Addition of specific antigen to the lung fragments induced the release of hista- 
mine,  SRS-A,  and ECF-A, whereas no activities were detected in the absence 
of antigen.  A  linear  dose-response curve was  obtained when  dilutions  of the 
TABLE I 
Antigen-Induced  Rdease  of ECF-A,  Histamine,  and SRS-A  from  Fragments of Actively 
Sensitized Guinea Pig Lung 
Eosinophil chemotaxis  Histamine  release  SRS-A 
mean cell count  ~g/g  units]g 
Lung +  antigen  21.5  4  450 
Lung +  diluent  1.6  0  0 
Zym G/P serum  18.6 
anaphylactic diffusate were tested for chemotaxis (Fig. 2). Replicate samples of 
sensitized  lung  fragments  therefore  provided  a  convenient  test  system  for 
investigating  both  the  antibody  involved  and  the  mechanism  of  release  of 
ECF-A. 
Selective Chemotactic Activity  of the Anaphylactic  D~usate for Eosinophils.-- 
Anaphylactic  diffusates were  examined for  eosinophil  and  neutrophil  chemo- 
tactic  activity using  a  suspension  of cells  rich  in  neutrophils  but  containing 
12 %  eosinophils.  Guinea pig serum treated with zymosan has both neutrophil 
and  eosinophil  chemotactic activity  (2)  but  attracted  only neutrophils  when 
millipores with a 1.2/z or 3.0/~ pore size were used. With an 8.0/~ pore size both 
eosinophils  and  neutrophils  migrate  towards  zym  G/P  serum,  the  ratio  of 
migrating eosinophils to neutrophils being ahnost the same as in the cell com- 
partment before migration commenced.  Chemotactic activity of the lung dif- 
fusate was detectable only with an 8.0 ~ pore size; 84% of the cells migrating 
were  eosinophils  although  only  12%  were  present  in  the  cell  compartment 
(Table II). The experiment was repeated using diffusates from actively or pas- 
sively  sensitized  lung  challenged  with  antigen.  On  these  occasions,  using  a A.  B.  KAY,  DANIEL  J.  STECIISCHULTE,  K.  FRANK  AUSTEN  607 
neutrophil-rich suspension and an 8.0/z millipore size, 100 %  of the cells migrat- 
ing towards the anaphylactic diffusate were eosinophils. Taken together these 
experiments demonstrated  a  selective chemotactic property for eosinophils of 
the anaphylactic lung diffusate. 
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FIG. 2.  Chemotactic dose-response curve following dilutions of lung diffusate  containing 
ECF-A. 
TABLE II 
Selective Chemotactlc Property of an Anaphylactic Lung Diffusate for IZosinophil Leukocytes 
Millipore size 
Eosinophil and neutrophil chemotaxis 
(mean cell co*,nt)* 
1.2/~  3.0/z  8.0/~ 
Anaphylactic lung diffusate 
Zym G/P serum 
Diluent 
1.2  +  1.4  2.2  +  0.6  14.2  +  4.6 
2.8  2.8  18.8 
0  +  12  0  +  13  6.4  +  26.4 
12  13  32.8 
0  0  0 
* Mean cell counts are expressed as (E + N)/T where E is the eosinophil count, 2Y the 
neutrophil count, and T the total mean cell count. The cell suspension contained 80% neutro- 
phils, 12% eosinophils, and 8% mononuclear  cells. 
Identification  of the Antibody Mediating  the Release  of ECF-A from  Guinea 
Pig Lung.--Analysis  of the sera obtained from the actively sensitized animals 
shown in Fig. 1 revealed a relationship between the passive cutaneous anaphy- 
laxis (PCA) titer of the sera and the histamine release from the donor animals 
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of histamine  and ECF-A  had circulating  antibody characteristic  of IgG1.  The 
antibody was heat stable and gave a high 4 hr PCA titer which at 48 hr showed 
a  falling  titer  of  one or two doubling dilutions. No evidence  was found of  an 
IgE-type  antibody. 
Direct  evidence  that  IgG1  mediated  the  release  of  ECF-A  was  sought  by 
experiments  in which lung fragments  were  passively  sensitized  with fractions 
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FIG. 3.  Ability of fractions of guinea pig IgG1 and IgG2, obtained by DEAE-cellulose 
chromatography, to passively sensitize lung fragments for the  antigen-induced release of 
ECF-A, histamine, and SRS-A. Antibody fractions 1-5 were diluted 1:50, fraction 6 was 
diluted 1  :  5. 
(Fr)  of guinea pig 7S IgG. Biologic evidence for separation of IgG1 and IgG2 is 
shown in F;g. 3.  Fractions  1-5  all agglutinated red cells which were  passively 
sensitized with  ovalbumin,  but only those cells  sensitized  with  the IgG~  con- 
taining fractions (Fr 1, 2, and 3) hemolyzed  on the addition of guinea pig com- 
plement.  PCA titers were  given only with the IgG1 containing fractions (Fr 4, 
5, and 6). Immunoelectrophoretic and gel diffusion studies with specific antisera 
to guinea pig  7S IgG1  demonstrated  IgG1  only in fractions 4,  5,  and 6.  Only 
those fractions which contained IgG1  (Fr 4, 5,  and 6) prepared lung fragments 
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these experiments, the dose of antigen,  the time of sensitization with antibody, 
and the time of incubation with antigen were arbitrarily chosen on the basis of a 
previous study (6). 
The heat stability of the antibody mediating the release of ECF-A was also 
determined and provided further evidence that IgG1 and not an IgE-type anti- 
body mediated its release. Fractions 4  and 5 were heated for 4 hr at 56°C  and 
when  compared  with  the  unheated  fractions  showed  no  difference  in  their 
ability to  mediate  the  release  of  histamine,  SRS-A  or  ECF-A  (Table  III). 
The Mechanism  of Release of ECF-A.-- 
Optimal  conditions for the release of ECF-A  after passive sensitization  of lung 
fragments:  The  optimal  conditions  required  for  the  release  of  ECF-A  after 
TABLE III 
Effect of Heat on the Ability  of IgG1 to Prepare Guinea Pig Lung  Fragments for the 
A ntlgen-lnduced Rdease of ECF-A, Histamine,  and SRS-A* 
Sensitization  Eosinophil chemotaxis  Histamine  release  SRS-A 
mean cell ~ount  ~g/g  nnits/g 
Fraction 4 
Unheated  12.7  1.5  50 
Heated  14.7  1.5  80 
Fraction 5 
Unheated  14.1  1.3  80 
Heated  14.4  1.3  70 
* Fractions were heated for 4 hr at 56°C and diluted 1  : 50.0.9 ml volumes of lung effluents 
were tested for chemotaxis  to which was added 0.1 ml of 5% ovalbumin. Control samples 
sensitized with fraction 4 or 5 but not challenged with antigen gave a background chemotactic 
count of less than 1.5. 
passive sensitization of normal lung were  determined as follows. Using a  21~ 
hr sensitization period and 200/~g of ovalbumin/300 mg of lung tissue, a  1:50 
dilution of an IgGl-containing fraction (Fr 4) was found to release more ECF-A 
than a  1:5 or a  1:500 dilution. The time course of sensitization of tissue with 
antibody is shown in Fig. 4. The release of ECF-A, histamine, and SRS-A was 
detectable after 10 min of sensitization, reached a peak at 1 hr,  and was main- 
tained for  at least 21/~ hr.  In further  experiments either  a  1  hr  or  a  21/'~ hr 
sensitization time was used. With regard to the time course of release, incuba- 
tion with  antigen beyond  15  min  did not result in greater release of ECF-A. 
With a  1 hr sensitization period and a  1 : 50 dilution of fraction 4  (IgG1) 20 and 
200/~g of ovalbumin yielded greater release of ECF-A, histamine, and SRS-A 
than 2  or 2,000/~g of ovalbumin/300 mg of lung (Fig. 5). 
The effect of decomplementation with cobra venom factor: Animals were depleted 
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cobra venom. Less than 5 %  of the circulating complement level was detectable 
10 hr after the administration of 2 units of purified cobra venom factor. Accord- 
ingly,  actively sensitized  animals  were  sacrificed  10  hr  after  injection,  their 
lungs removed, perfused, and sliced as described above and portions challenged 
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Fro. 4. Time course of passive sensitization  of lung fragments by an IgGl-Containing frac- 
tion (fraction 4 diluted 1:50) for the antigen-induced release of ECF-A, histamine, and SRS-A. 
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FIG. 5. Effect of antigen concentration  on the release of ECF-A, SRS-A, and histamine from 
guinea  pig lung passively sensitized with IgG1  (fraction  4  diluted 1:50). 
with  specific  antigen.  Table  IV  shows  that  there  was  no  difference  in  the 
amounts  of  ECF-A released from  lungs  of  cobra venom-treated  animals  and 
untreated  animals. Although  absolute histamine release in  the  actively sensi- 
tized animals appeared to be somewhat  affected by venom treatment,  the per A.  B.  KAY,  DANIEL  J'.  STECI-ISCHULTE,  K.  FRANK  AUSTEN  611 
cent release was  similar in the  two groups,  being in animals one to  six 31.0, 
37.5, 31.0, 43.2, 36.2, and 35.2 respectively. 
An experiment was  also performed using normal animals whose circulating 
complement levels were depleted with cobra venom factor and whose lungs in 
the  same  manner  as  described  were  then  passively sensitized  with  a  1:50 
dilution of fraction 4  (IgG1). Virtually identical results were obtained as with 
lungs from actively sensitized animals (Table IV). 
TABLE IV 
Effect of Complement Depletion In  Vivo on  the In  Vitro Rdease of ECF-A,  Itistamine,  and 
SRS-A from Guinea Pig Lung Fragments* 
Change in hemolytic  Eosinophil  Histamine  Animal  Treatment  titer of the terminal  SRS-A 
No.  complement components  chemotaxis  release 
mean cell 
count  tzg~g  units/g 
Actively sensitized lung 
1  Cobra venom factor  5120 -~  160  26.1  5.5  400 
2  ' .....  5120 ~  80  34.4  7.0  520 
3  ......  5120 --* 160  30.3  5.5  550 
4  Tyrode's solution  5120 --~ 5120  35.1  9.5  1000 
5  ....  5120 ~  5120  29.7  7.1  620 
6  ....  5120 ~  5120  34.2  9.5  1100 
Passively sensitized lung 
7  Cobra venom factor  10,240  --~ 640  17.4  4.0  500 
8  ......  10,240 -~ 640  16.1  3.6  400 
9  ......  10,240 --~ 640  15.5  3.5  400 
10  Tyrode's solution  10,240 --~  10,240  16.7  3.3  1000 
11  ....  10,240 --~  10,240  15.0  3.6  750 
* With animals 1-6, 0.9 ml volumes of lung effluent were tested for chemotaxis and with 
animals 7-11, 0.6 ml volumes were used. Lung fragments suspended in Tyrode's alone gave 
background counts of less than 3.4 and 0 in the two experiments, respectively. Lungs were 
passively sensitized for 21/~ hr with a 1  : 50 dilution of fraction 4. 
Inhibition and enhancement:  A requirement of divalent cations for the release 
of  ECF-A was  determined by experiments in which  actively sensitized lung 
was challenged with antigen in the presence of 5  rnM of EDTA (Table V). In 
the  absence of  calcium and magnesium ions, there was no release of ECF-A, 
histamine, or  SRS-A. Before  testing for  chemotaxis,  calcium and magnesium 
ions were added to the diffusates containing EDTA. Tyrode's EDTA in which 
the divalent cations had been replaced served as a control in that this solution, 
together with antigen, was used to challenge sensitized lung for ECF-A release 
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cations fully restored antigen-induced release of ECF-A, histamine, and SRS-A. 
The experiment was repeated with passively sensitized lung and gave the same 
result. 
The capacity of succinate and maleate to enhance the release of histamine and 
SRS-A (12)  was  also sought in terms of ECF-A release. When  actively sensi- 
tized lung was  used,  the enhancement  of ECF-A release in the presence  of 5 
TABLE V 
Effect  of EDTA  on  the Antigen-Induced  Rdease  of ECF-A,  Histamine,  and  SRS-A  from 
Activdy Sensitized Guinea Pig Lung Fragments 
Eosinophil Histamine  Suspending medium for lung fragments  Challenge  chemotaxis  release  SRS-A 
5 m~ EDTA in Tyrode's  Antigen 
5 mM EDTA in Tyrode's with  Ca  ++,  Mg  ++  Antigen 
replaced 
Normal Tyrode's solution  Antigen 
Normal Tyrode's solution  Tyrode's 
mean cell 
count  #gig  units/g 
0.4  0  0 
20.4  9  100 
24.6  8  110 
3.6  0  0 
TABLE VI 
Effect of Succinate and Maleate on the Antigen-Induced Release of ECF-A and Histamine from 
Actively Sensitized Guinea Pig Lung Fragments 
Suspending medium for lung fragments 
Eosinophil chemotaxis (mean cell count) 
Volume of lung diffusate assayed  Histamine  release 
0.6 ml  0.3 ml  0.15 ml 
p-g/g 
Antigen Mth 5 m~ succinate in Tyrode's  30.8  30.2  16.2  3.0 
Antigen with 5 mM maleate in Tyrode's  31.8  26.2  18.2  3.5 
Antigen in Tyrode's (succinate)*  26.2  17.0  7.8  1.6 
Antigen in Tyrode's (maleate)*  25.0  16.2  8.0  1.6 
Tyrode's solution  1.2  0.0  0.0  0.0 
* Succinate  (5 raM) added to chemotactic chamber. 
:~ Maleate (5 m~) added to chemotactic chamber. 
mu  of succinate  or maleate approximated the  augmentation  of histamine re- 
lease (Table VI). When the usual volume of 0.6 ml of lung diffusate was used, 
the enhancement was less apparent than when smaller volumes were employed. 
The  experiment  was  repeated  using  lung  fragments  passively  sensitized  for 
21/~ hr with  a  1:50  dilution of IgG1 (Fr 4);  5  mM succinate or maleate again 
strikingly  enhanced  the  release  of  ECF-A  and  histamine.  SRS-A  was  not 
measured  in  these  enhancement  experiments. 
Differentiation  of ECF-A from  the Other Pharmacological  Mediators  of Ana- TABLE VII 
Experiments  to  Show  that  Histamine,  Bradykinin,  Serotonin,  Prostaglandins  El,  E2,  and 
F2a  are not Chemotactic for Eosinophils Per Se and are not Responsible for  the  Release  of 
these Agents 
Eosinophil chemotaxis 
mea~ cell count 
Experiment 1 
Lung %- antigen  27.1 
Lung %- Tyrode's  2,6 
Lung %- histamine (0.5/zg/ml)  3.0 
Lung %- histamine (5/zg/ml)  4.4 
Histamine (0,5/~g/ml)  0.0 
Histamine (5/zg/ml)  0.0 
Experiment 2 
Lung +  antigen 
Lung %- Tyrode's 
Lung %- bradykinin (0.01/lg/ml) 
Lung %- bradykinin (0.1 #g/ml) 
Lung %- bradykinin (1.0 #g/ml) 
Bradykinin (1.0/~g/ml) 
Lung %- serotonin (0.01/~g/ml) 
Lung %- serotonin (0.1 #g/ml) 
Lung %- serotonin (1.0/zg/ml) 
Serotonin  (1.0 pg/ml) 
20.4 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
Experiment 3 
Lung +  antigen  17.0 
Lung +  Tyrode's  3.2 
Lung +  PGE1 (0.01/zg/ml)  1.0 
Lung +  PGE1 (0.1/~g/ml)  2.0 
Lung +  PGE1  (1.0 #g/ml)  0.6 
PGEx (1.0 #g/ml)  0.0 
Lung +  PGE2 (0.01/zg/ml)  1.0 
Lung %- PGE2  (0.1/zg/ml)  1.0 
Lung +  PGE2  (1.0 #g/ml)  1,4 
PGE2  (1.0 #g/ml)  0,0 
Lung +  PGF~ (0.01/zg/ml)  1,0 
Lung %- PGF~ (0.1/zg/ml)  1.0 
Lung %- PGF~ (1.0/~g/ml)  3.4 
PGF2~ (1.0 ]~g/ml)  0.0 
Experiment 4 
Lung +  antigen  16.6 
Lung +  Tyrode's  0.0 
Lung +  SRS-A* (15 units/ml)  2.0 
Lung +  SRS-A (30 units/ml)  0.6 
SRS-A (50 units/ml)  4.0 
* The SRS-A was prepared by boiling an SRS-A ethanol extracted preparation in 0.05 
z,l NaOtt for 10 rain. Before boiling in alkali the preparation had 50 units of SRS-A/ml and 
an eosinophil chemotactic count of 61.0. 
The histamine release in micrograms  per milliliter of lung diffusate  was 0.5, 0.25, 0.35, 
and 0.13 in experiments  1, 2, 3, and 4, respectively. 
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phylaxis.--In order to determine whether ECF-A was in fact an already recog- 
nized pharmacological agent, various chemical mediators of anaphylaxis were 
tested directly for their ability to evoke the  migration of eosinophils  (Table 
VII). It was found that histamine,  bradykinin, serotonin, and prostaglandins 
PGE1,  PGE,,  and  PGF,~  were  not  chemotactic for  eosinophils  per  se;  and, 
furthermore, when incubated with sensitized lung in  the  absence of antigen, 
these agents did not secondarily affect the release of ECF-A. The 0.5/~g dose 
of histamine used in experiment 1 was comparable to the amount of histamine 
released from the same lung by specific antigen. 
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I"IG. 6. Effect on ECF-A and SRS-A activity of boiling in acid or alkaline solutions. 
Some crude preparations of SRS-A were chemotactic for eosinophils. These 
were obtained by extraction of lung diffusates in 80 % ethanol, removal of the 
precipitate  by  centrifugation,  and  evaporation  to  dryness  of  the  supernate 
under vacuum using a rotary evaporator. The extracted material was reconsti- 
tuted in distilled water. It was possible, however, to differentiate ECF-A and 
SRS-A activity by boiling the crude material in alkaline solution. Since it had 
been previously reported that SRS-A survives boiling in 0.05 N NaOH but not 
in 0.05 ~," HC1 (13), the behavior of ECF-A under these conditions was investi- 
gated.  As seen in Fig.  6,  ECF-A activity rapidly disappeared after boiling in 
acid or neutral solution and even more rapidly when boiled in alkali. In these 
experiments, the preparations were immediately adjusted to neutral pH before 
testing for SRS-A and chemotaxis. Thus by boiling in alkali, it was possible to 
destroy all ECF-A without influencing SRS-A activity (Table VII). It was also A.  B.  KAY,  DANIEL  J.  STECHSCHULTE,  K.  FRANK  AUSTEN  615 
possible to separate ECF-A from SRS-A by Sephadex G-25  chromatography 
(Fig. 7, vide infra).  The peak of SRS-A activity was usually ill defined but ap- 
peared  after ECF-A. 
Differentiation of ECF-A from ECF-C.--ECF-A partially survived ethanol ex- 
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Fro.  7.  Sephadex G-25 chromatography of anaphylactic lung diffusate and  zymosan- 
treated guinea pig serum. Even numbered fractions from tubes 10-48 were tested for chemo- 
taxis. 
traction suggesting  that  its biological activity is  not  associated with  a  large 
molecule; for this reason, a lung diffusate having high chemotactic activity was 
applied to a column of Sephadex G-25. In each of six experiments,  five using 
material from actively sensitized lung and one from a passively sensitized lung, 
the peak of eosinophil chemotactic activity eluted after the fractions containing 
the molecular marker glucagon (mol. wt. 3485)  and vitamin B12 (mol. wt. 1357) 
but before histamine acid phosphate (tool. wt. 310)  (Fig. 7). Thus, the molecu- 
lar weight of ECF-A is thought to be approximately 500-1000. 616  EOSINOPHIL  CHEMOTACTIC  FACTOR  IN  ANAPHYLAXIS 
In  order  to  calculate  the  per  cent  recovery of  ECF-A  following passage 
through a Sephadex column, advantage was taken  of the linear dose response 
for chemotaxis when dilutions are made of material containing ECF-A  activity 
(Fig. 2). In this way, it was possible to obtain an arbitrary chemotactic value 
for an ECF-A preparation in relation to one preparation of target cells.  When 
the same cells  were tested against fractions of the ECF-A preparation, it was 
possible  to  demonstrate  a  100%  recovery of  ECF-A  activity  after  passage 
through a column of Sephadex G-25. 
It has been shown that ECF-C, produced either by treating whole serum with 
antigen-antibody complexes (1)  or with zymosan,  2 has  a  molecular weight of 
approximately  15,000.  As  shown  in  Fig.  7,  ECF-C  activity from zymosan- 
treated serum was excluded by Sephadex G-25. 
DISCUSSION 
The capacity of actively (Table I) or passively (Fig. 3) sensitized guinea pig 
lung to react with antigen to release a factor chemotactic for eosinophil leuko- 
cytes (ECF-A) has been demonstrated. In all experiments, the release of ECF-A 
was also accompanied by the release of both histamine and SRS-A. Indeed, the 
release of all these mediators exhibited a similar reponse in terms of the time 
course of passive sensitization (Fig. 4), the effect of antigen dose (Fig. 5), and 
the time course of release. Furthermore, the release of ECF-A was dependent 
on divalent cations (Table V)  and was strikingly enhanced by the presence of 
succinate or maleate (Table VI). These features are again characteristic of the 
release of histamine and SRS-A (12, 14). 
It  has  previously been  demonstrated  that  guinea  pig  IgG1  can  passively 
sensitize guinea pig lung slices for the antigen-induced release of histamine (6) 
and SRS-A (7), and this same immunoglobulin has been shown to mediate the 
release of ECF-A  (Fig. 3). The fractions which prepared tissue for ECF-A re- 
lease (Fr 4 and 5) lost no activity after heating at 56°C for 4 hr (Table III), a 
property characteristic of IgG1  but not  of an  IgE-like immunoglobulin.  The 
IgG2-containing fractions, having hemagglutinating activity virtually equal to 
that of IgG1 fractions, failed to prepare lung fragments for the antigen-induced 
release of histamine, SRS-A, or ECF-A (Fig. 3). 
Since guinea pig IgG1  appears  capable  of mediating the release  of several 
pharmacologic agents,  it was necessary to exclude the possibility that ECF-A 
was an already recognized chemical mediator or was released secondary to the 
presence of other reaction products recognized herein. Histamine, SRS-A, and 
the prostaglandins PGE1, PGE2, and PGF2~ were not eosinophilotactic per se; 
neither was ECF-A detected after the incubation of these agents with sensitized 
lung in the absence of antigen (Table VII). Studies with sensitized guinea pig 
lung (15,  16) have shown the release of kallikrein after antigen challenge; this 
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reaction with  kininogen,  namely bradykinin,  was  not itself  chemotactic for 
eosinophils and did not secondarily affect the release of ECF-A (Table VII). 
Similar findings were observed with serotonin (Table VII). 
Since  eosinophilotactic activity could still be  detected  after  extraction  of 
anaphylactic lung diffusate in 80%  ethanol and evaporation to dryness, the 
possibility was considered that SRS-A contained chemotactic activity. Reasons 
for considering ECF-A as separate from SRS-A are that SRS-A survived boiling 
in alkaline solution for 20 rain whereas ECF-A activity was abolished by this 
procedure (Fig. 6); and in addition SRS-A and ECF-A could be separated by 
gel filtration (Fig. 7). 
The finding that ECF-A generation is  a  consequence of antigen-antibody 
interaction and dependent upon the presence of divalent cations raises the ques- 
tion of whether it is identical with the eosinophilotactic factor formed in guinea 
pig  serum  following  treatment  with  immune  complexes  (1)  or  zymosan3 
ECF-C produced in vitro by antigen-antibody complexes,  prepared either with 
IgG1 or IgG2 and antigen, requires the participation of complement since ECF-C 
is  not generated from serum heated at 56°C for 30  min or from ammonia- 
treated serum or from serum activated in the presence of 0.01 1~ EDTA (1). No 
evidence was found, however,  that ECF-A generation was dependent on an 
intact complement system. Guinea pig lung, perfused free of visible blood and 
then cut in slices and thoroughly washed was capable of being passively sensi- 
tized with an IgGl-containing fraction (even after heating for 4 hr at 56°C) for 
the subsequent antigen-induced release of ECF-A (Table III, Fig. 3). Further- 
more, depleting the donor animals of 95 % of the circulating complement level 
had no effect on the capacity of their isolated lung fragments to yield ECF-A 
after passve sensitization and antigen challenge (Table IV). Decomplementa- 
tion was accomplished by the administration of purified cobra venom factor, a 
procedure which depletes C3 and to a lesser extent the complement components 
acting thereafter (17, 18). This maneuver also had no effect on the antigen-in- 
duced release of ECF-A from lung fragments from actively sensitized animals 
(Table IV). 
ECF-A and ECF-C can be distinguished not only in terms of the complement 
requirement for their generation but also by their apparent size differences as 
determined by gel filtration. On Sephadex G-25,  ECF-C is excluded as shown 
by the molecular marker blue dextran (Fig. 7),  consistent with its previously 
reported molecular weight of approximately 15,000 (1). In contrast, ECF-A ap- 
peared after the molecular marker vitamin B12 (mol. wt. 1357) but before hista- 
mine acid phosphate (tool. wt. 310),  suggesting a molecular weight of approxi- 
mately 500-1000  (Fig. 7). It should further be noted that the complete recovery 
of ECF-A in the diffusate introduced onto the Sephadex column indicated that 
the eosinophilotactic activity of the lung diffusate is unlikely to be a mixture of 
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In a  cell suspension containing predominantly neutrophils,  only eosinophils 
migrated towards ECF-A whereas zymosan-treated serum, which contains both 
ECF-C  and  NCF-C  (1),  2 attracted  both  neutrophils  and  eosinophils in  the 
same proportion as was present in the original cell suspension (Table II). Thus, 
ECF-A represents a hitherto undescribed agent which, like ECF-C, selectively 
attracts eosinophil leukocytes. 
SUMMARY 
The capacity of actively or passively sensitized guinea pig lung to react with 
antigen  to  release  a  factor specifically chemotactic for eosinophil leukocytes 
(ECF-A) has been demonstrated. The release of ECF-A was also accompanied 
by the elaboration of both histamine and SRS-A and the appearance of all these 
mediators exhibited a  similar response in terms of the  time  course  of  passve 
sensitization, the effect of antigen dose, the time course of release, divalent ca- 
tion  dependence and  enhancement by the  presence of succinate  or  maleate. 
Decomplementation by the administration of purified cobra venom factor had 
no effect on the antigen-induced release of ECF-A from actively or passively 
sensitized lung fragments. 
When fragments of guinea pig lung were passively sensitized with fractions of 
guinea pig 7S IgG, only the IgGl-containing fractions prepared tissue for the 
antigen-induced release of ECF-A.  Histamine,  SRS-A,  bradykinin,  serotonin, 
and  the prostaglandins  PGE1,  PGE~,  and  PGF2~  were not eosinophilotactic 
per se;  neither was ECF-A  detected following the incubation of these agents 
with sensitized lung in the absence of antigen. 
Both  eosinophilotactic  activity  and  SRS-A  survived  extraction  in  80% 
ethanol and evaporation to dryness. SRS-A, however, withstood boiling in alka- 
line solution for 20  rain,  whereas ECF-A  activity was  abolished by this  pro- 
cedure. SRS-A and ECF-A could also be separated by gel filtration. ECF-A ac- 
tivity  was  completely recovered following its  passage  through  a  column  of 
Sephadex G-25 and had an estimated molecular weight of between 500 and 1000. 
On the basis of size and a formation mechanism independent of the complement 
system, ECF-A is distinguishable from a previously described complement-de- 
pendent eosinophilotactic factor (ECF-C). Thus, ECF-A represents a hitherto 
undescribed agent which selectively attracts eosinophil leukocytes. 
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